Laurus Labs Q2 FY27 Earnings Call — Analysis (NSE: LAURUSLABS)
Laurus Labs delivered record Q2FY27 revenue of ₹2,206 Cr and an EBITDA margin of 34.5%, driven by an 86% YoY surge in small molecule CDMO and strong operational leverage.
Result quality: stable — Results context unavailable. Management sentiment: optimistic.
The take
H1FY27 Total Income from Operations ₹4,233 Cr ( +31% YoY ) . New guidance — FY28 fy27-fy28 capex program ₹3,000 Cr . New story: CDMO High-Complexity Expansion .
Results
Revenue reached ₹2,206 Cr with EBITDA of ₹762 Cr (34.5% margin, +270bps QoQ) and PAT of ₹441 Cr, propelled by 86% growth in CDMO.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Total Income from Operations | ₹2,206 Cr | none · Q2FY27 · record quarterly revenue | |
| Total Income from Operations | ₹4,233 Cr | +31% | yoy · H1FY27 · vs H1FY26 |
| Gross Margin | 63.0% | sequential · Q2FY27 · vs Q1FY27 | |
| EBITDA | ₹762 Cr | none · Q2FY27 | |
| EBITDA Margin | 34.5% | +270bps | sequential · Q2FY27 · expanded by 2.7 percentage points over Q1FY27 |
| EBITDA | ₹1,406 Cr | none · H1FY27 · 33.2% margin | |
| Profit After Tax | ₹441 Cr | none · Q2FY27 | |
| Profit After Tax | ₹809 Cr | none · H1FY27 | |
| ROCE | 22.5% | +480bps | yoy · H1FY27 · vs 17.7% in FY26 |
| CDMO Revenue | ₹875 Cr | +86% | yoy · Q2FY27 · vs Q2FY26 |
| CDMO Revenue | ₹1,710 Cr | +77% | yoy · H1FY27 · vs H1FY26 |
| Affordable Medicines Revenue | ₹1,302 Cr | +15% | yoy · Q2FY27 · vs Q2FY26 |
| Affordable Medicines Revenue | ₹2,459 Cr | +13% | yoy · H1FY27 · vs H1FY26 |
| Laurus Bio Revenue | ₹29 Cr | none · Q2FY27 | |
| Laurus Bio Revenue | ₹64 Cr | none · H1FY27 | |
| Capital Expenditure | ₹470 Cr | none · Q2FY27 | |
| Capital Expenditure | ₹864 Cr | none · H1FY27 | |
| Net Debt | ₹2,466 Cr | point_in_time · Q2FY27 · Sep-2026 |
Guidance
Management maintained annual guidance of >60% gross margin and >30% EBITDA margin while committing to a ₹3,000 Cr capex program over FY27–FY28.
What management committed to
- [Laurus Labs] will invest INR 3,000 crores capex across '27 to '28 (~INR 1,500 crores per year). — INR 3,000 crores, FY28
- [Laurus Labs] is comfortable maintaining over 60% gross margin and over 30% EBITDA margin. — over 30% EBITDA, FY27
- [Laurus Bio 4 (LB4) 500,000-liter fermentation facility] will be operational by the end of this year, with validation trials in Q4FY27 and commercial supplies starting in Q1 FY28. — Q1FY28
- [KRKA Joint Venture formulation facility] Phase 1 production blocks are scheduled to commence operations in mid-2027 with validations, and meaningful revenues starting in '28, '29. — FY28
- Validation batches for the [peptide manufacturing facility] are expected within a 12 to 18 months timeframe, with commercial revenues around 2029. — FY29
Key themes
CDMO momentum and complex modality expansion
How the narrative shifted
- CDMO High-Complexity Expansion: Laurus is evolving into an integrated end-to-end partner for complex modalities (peptides, oligos, ADCs) rather than commoditized small molecules.
- Targeted Backward Integration via M&A: Inorganic acquisitions (Galenvs, SI & C Resins) are deployed to acquire specific technological competencies and ensure raw material security for peptide/oligo synthesis.
- Affordable Medicines Margin Stability: Pricing in ARVs and developed market formulations has stabilized, providing steady cash flow to fund high-value CDMO investments.
- Capex Allocation and Cash Flow Balancing: Management is willing to absorb near-term neutral free cash flows to aggressively fund growth capex given net debt to EBITDA is low (~1.02x).
Operational commentary
- Commissioned commercial-scale peptide manufacturing block; solid-phase peptide synthesis (SPPS) reactor capacity stands at over 16,000 liters with end-to-end integrated API capabilities (synthesis, purification, isolation).
- Announced 60% majority acquisition of Canada-based Galenvs Sciences to enter early-stage oligonucleotide development and precision magnetic nanoparticles purification.
- Announced majority stake acquisition in SI & C Resins to secure internal supply of solid support resins and chromatography stationary phases for peptide manufacturing.
- Commercialized an OEB 5 facility dedicated to payload linkers for Antibody Drug Conjugates (ADCs).
- Small molecule API operational reactor capacity reached over 9,000 kiloliters.
- Laurus Bio 4 (LB4) commercial fermentation capacity of 500,000 liters is on track for qualification by end of FY27, trials in Q4FY27, and commercial supplies in Q1FY28.
- KRKA joint venture formulation facility Phase 1 blocks scheduled to commence operations/validations in mid-2027 with commercial revenue expected in FY28/FY29.
Analyst Q&A
Q. What is the timeline and revenue quantum for commercial-scale peptide capacity?
Commercial revenues from current peptide capacities are expected around 2029, with validation campaigns driving utilization over the next 12-18 months. Capex quantum and asset turns were withheld for confidentiality reasons.
Q. What drove the sequential revenue ramp in CDMO and are there customer inventory buildup risks?
The growth was broad-based execution across commercial and late-stage programs without one-off spikes, and management does not anticipate sudden inventory destocking surprises.
Q. What is the breakdown of CDMO pipeline molecules across Phase I, II, III, and commercial?
Management declined to provide project counts across phases, stating project counts do not correlate linearly with revenue due to wide project size variation ($200k to tens of millions).
Q. Why did H1 operating cash flow decline and how will free cash flow pan out against ₹3,000 Cr capex?
Inventory increase was standard operating inventory that will normalize in coming quarters. Management prioritised growth capex over near-term free cash flow given strong balance sheet leverage at ~1.02x Net Debt/EBITDA.
Research and educational content only. Not investment advice.